Category Archives: regulatory

FDA Publish Guidance for Industry; Q3C – Tables and Lists

This document may be updated if proposals for change are submitted to the International Conference on Harmonisation (ICH) Steering Committee. Proposals for change and the ICH Steering Committee final decision on any proposed changes will be announced through a notice in the Federal Register prior to the updating of this document. The guidance was revised in November 2003 to reflect updated recommendations for N-Methylpyrrolidone and Tetrahydrofuran and in February 2012 to reflect an updated recommendation for cumene.

For further details, please view the document below.

FDA Publish Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members’ Financial Interest Information and Waivers

Advisory committees provide independent, expert advice on scientific, technical, and policy matters related to the development and evaluation of products regulated by FDA, such as human and animal drugs, biological products, medical devices, foods, and tobacco products. The advisory committee system enhances FDA’s ability to protect and promote the public health and maintain the public trust by enabling the agency to obtain the benefit of independent, professional expertise. Although advisory committees provide recommendations to FDA, final decisions are made by FDA. See 5 U.S.C. App. 2 § 9(b); 21 CFR 14.5.

For further details, please view the document below.

MHRA Publish ‘The Blue Guide’ – Advertising and Promotion of Medicines in the UK

There is a specific licensing system for medicines, operated in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is the Government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe. Its work is underpinned by robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks. Its licensing schemes cover the whole range of medicines for human use, from registration for herbal and homeopathic remedies to marketing authorisation for the latest innovative advanced technology medicinal products. This guide uses the general term ‘licence’ to refer to all these schemes.

For further details, please view the document below.
http://damienbove.com/pdf/con149609.doc

FDA Publish Guidance; Media Fills for Validation of Aseptic Preparations for Positron Emmision Tomography (PET) Drugs

This guidance is intended to help manufacturers of positron emission tomography (PET) drugs meet the requirements for the Agency’s current good manufacturing practice (CGMP) regulations for PET drugs (21 CFR part 212). Most PET drugs are designed for parenteral administration and are produced by aseptic processing. The goal of aseptic processing is to make a product that is free of microorganisms and toxic microbial byproducts, such as bacterial endotoxins. A media fill is the performance of an aseptic manufacturing procedure using a sterile microbiological growth medium, in place of the drug solution, to test whether the aseptic procedures are adequate to prevent contamination during actual drug production. Media fill procedures recommended in this guidance apply only to sterile PET drugs manufactured by aseptic processes under 21 CFR part 212.

For further details, please view the document below.

ICH Publish E2C(R2) Periodic Benefit-Risk Evaluation Report

The E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER) described in this guideline is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the ICH regions. Regulators from EU, Japan, and the US believe that the PBRER may be used to meet prevailing national and regional requirements for periodic safety and/or benefit-risk reports for approved medicinal products.

For further details, please view the document below.

FDA Publish Guidance for Industry and Food and Drug Administration Staff; FDA and Industry Procedures for Section 513(g) Requests for Information Under the Federal Food, Drug and Cosmetic Act

Pursuant to section 513(d) of the FD&C Act (21 U.S.C. 360c(d)), FDA promulgates classification regulations classifying devices by generic type. A “generic type of device” is “a grouping of devices that do not differ significantly in purpose, design, materials, energy source, function, or any other feature related to safety and effectiveness, and for which similar regulatory controls are sufficient to provide reasonable assurance of safety and effectiveness.” (See 21 CFR 860.3(i)). FDA has issued regulations classifying the vast majority of pre-amendments devices (devices that were in commercial distribution before May 28, 1976) by generic type of device. See 21 CFR 860.84. Each classification regulation, located at 21 CFR parts 862-892, indicates in which class (I, II, or III) FDA has classified the device type. While the great majority of device classifications codified in 21 CFR parts 862-892 are of pre-amendments devices, some of these classifications are of post-amendments devices.

For further details, please view the document below.

FDA Publish Guidance for Industry; Statistical Evaluation of Stability Data

The guidance on the evaluation and statistical analysis of stability data provided in the parent guidance is brief in nature and limited in scope. The parent guidance states that regression analysis is an appropriate approach to analyzing quantitative stability data for retest period or shelf life estimation and recommends that a statistical test for batch poolability be performed using a level of significance of 0.25. However, the parent guidance includes few details and does not cover situations where multiple factors are involved in a full- or reduced-design study.

For further details, please view the document below.

EMA Publish Points to Consider on the Evaluation of Diagnostic Agents

This document aims to outline the principles for the evaluation of efficacy of diagnostic agents that are intended for in vivo administration. Such uses may include, but are not limited to, structure delineation, functional assessment including biological and physiological processes, detection or assessment of diseases or pathology as well as prognostic/therapeutic management guidance. Any proposed therapeutic use of diagnostic agents would not be covered here.

For further details, please view the document below.

NICE Identifying and Managing Tuberculosis among Hard-toreach Groups

This guidance aims to improve the way tuberculosis (TB) among hard-to-reach groups is
identified and managed. It sets out how commissioners and services can achieve this. The
recommendations cover strategic oversight and commissioning of TB prevention and control activities, local needs assessment, cohort review, commissioning multidisciplinary TB support for hard-to-reach groups(…)

For further details, please view the document below.

FDA Publish Regulation of PET Drug Products; Questions and Answers

This guidance is intended to help producers of positron emission tomography (PET) drugs meet the requirements for FDA’s drug approval process. This guidance provides questions and answers that address nearly all aspects of the drug regulatory process, including application submission, review, compliance with current good manufacturing practices, inspections, registration and listing, and user fees.

For further details, please view the document below.

FDA Publish Guidance for Industry; Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

This guidance gives an overview of FDA’s approach to determining biosimilarity, consistent with a longstanding Agency approach to evaluation of scientific evidence. FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity, and recommends that sponsors use a stepwise approach in their development of biosimilar products.

For further details, please view the document below.

FDA Publish Guidance for Industry; Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product

The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) amends the PHS Act and other statutes to create an abbreviated licensure pathway in section 351(k) of the PHS Act for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed biological reference product (see sections 7001 through 7003 of the Patient Protection and Affordable Care Act (Pub. L. 111-148) (Affordable Care Act)). The BPCI Act also amended the definition of biological products to include “protein (except any chemically synthesized polypeptide)” (see section 351(i)(1) of the PHS Act).

For more details, please view the document below.

FDA Publish Guidance for Sponsors, Investigators, and Institutional Review Boards; Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)

In the Federal Register (FR) of January 4, 2011 (76 FR 256), FDA published a final regulation (21 CFR § 50.25(c)) amending the current informed consent regulations to require that informed consent documents and processes for applicable drug (including biological products) and device clinical trials include a specific statement that clinical trial information will be entered into a databank.The databank referred to in this final rule is the clinical trial registry databank maintained by the National Institutes of Health/National Library of Medicine (NIH/NLM) which was created by statute.

For more details, please view the document below.

EMA Publish Note for Guidance on the Format and Content of the Annual Report on the State of Development of an Orphan Medicinal Product

Article 5(10) of Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products requires sponsors to submit annual reports on the state of development of designated medicinal products to the European Medicines Agency (EMA). This guideline is intended to provide advice on the preparation of these reports. Annual reports are specific to each designation. As a consequence, when one active substance is the subject of several designations, a separate report should be prepared for each designation.

For further details, please view the document below.

FDA Publish M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

Although the ICH M3(R2) guidance is still in its early phases of implementation, the complexity of the guidance, its broader scope, and numerous changes in recommendations from the M3(R1) guidance have generated questions that have an impact on its successful implementation. This document is the first set of Q&As addressing Limit Dose for Toxicity Studies, Metabolites, and Reversibility of Toxicity, and was finalized at Step 4 in June 2011.

For more details, please view the document below.

EMA Publish Procedural Advice on Fee Reductions for Designated Orphan Medicinal Products

Orphan medicinal products designated in accordance with Regulation (EC) No 141/2000 of 22 January 2000, are eligible for reductions on all fees payable under Union rules pursuant to Regulation (EC) No 726/2004. This includes fees for pre-authorisation activities such as protocol assistance (scientific advice), and for products using the centralised procedure: the application for marketing authorisation, inspections and post-authorisation activities such as variations, annual fees, etc.

For further details, please view the document below.

FDA Publish Guidance for Industry; Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations

This guidance provides recommendations for sponsors of new drug applications (NDAs) and biologics license applications (BLAs) for therapeutic biologics regulated by CDER regarding in vitro and in vivo studies of drug metabolism, drug transport, and drug-drug or drug-therapeutic protein interactions.This guidance reflects the Agency’s view that the pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.

For more details on this subject, please view the document below.

EMA Publish Qualification Opinion of Low Hippocampal Volume (atrophy) by MRI for use in Clinical Trials for Regulatory Purpose in the Pre-dementia Stage of Alzheimers Disease

The European Medicines Agency’s (EMA) qualification process is a new, voluntary, scientific pathway leading to either a CHMP opinion or a Scientific Advice of novel methodologies on innovative methods or drug development tools. It includes qualification of biomarkers developed by consortia, networks, public/private partnerships, learned societies or pharmaceutical industry for a specific intended use in pharmaceutical research and development.

For further details, please view the document below.

NICE Publish Apixaban for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Adults

Apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) is an anticoagulant that
affects the blood coagulation cascade by directly inhibiting activated factor X
(factor Xa), so inhibiting thrombin formation and the development of thrombi. The recommended dosage of apixaban in the summary of product characteristics is 2.5 mg orally twice daily.The duration of treatment depends on the individual risk of the patient for venous thromboembolism, which is determined by the type of orthopaedic surgery.

For more details, please view the document below.

EMA Publish Guidance on Centrally Authorised Products Requiring a Notification of a Change for Update of Annexes

On 23 July 2010 and after a consultation phase, the EMA communicated to all Parallel Distributors that it is not required to inform the EMA on changes to the labelling or leaflet related to any update of the annexes, except for those when the EMA has specifically indicated that a notification of a change is still required. The following table lists the centrally authorised products that the EMA requires to submit a notification of change before implementation due to safety or quality reasons.

For further details, please view the document below.